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Abstract
Multiple myeloma (MM) is the second most common hematological malignancy in adults. It is characterized by clonal 
proliferation of terminally differentiated B lymphocytes and over-production of monoclonal immunoglobulins. 
Recurrent genomic aberrations have been identified to contribute to the aggressiveness of this cancer. Despite a 
wealth of knowledge describing the molecular biology of MM as well as significant advances in therapeutics, this 
disease remains fatal. The identification of biomarkers, especially through the use of mass spectrometry, however, 
holds great promise to increasing our understanding of this disease. In particular, novel biomarkers will help in the 
diagnosis, prognosis and therapeutic stratification of MM. To date, results from mass spectrometry studies of MM have 
provided valuable information with regards to MM diagnosis and response to therapy. In addition, mass spectrometry 
was employed to study relevant signaling pathways activated in MM. This review will focus on how mass spectrometry 
has been applied to increase our understanding of MM.
Multiple Myeloma
Multiple myeloma (MM), the second most common
blood cancer in adults, is a neoplasm of terminally differ-
entiated B-cells characterized by clonal expansion of
malignant plasma cells in the bone marrow. The most
common symptoms associated with MM include lytic
bone lesions, renal failure, calcium dysregulation, anemia
and susceptibility to infections. The median age at diag-
nosis of MM is 62 years for men and 61 years for women,
with less than 2% of those diagnosed at an age less than
40 years. The incidence of MM in the USA is more com-
mon among men (7.1 per 100,000) than women (4.6 per
100,000). In addition, MM is two times more frequent in
the black population than in the white population [1].
Despite advances in clinical care, MM remains an almost
universally fatal disease with a median survival of 3-4
years following conventional treatment and 5-7 years
with high dose therapy followed by autologous stem cell
transplantation [1].
The development of MM constitutes a series of pro-
gressive genetic events. A seminal event is the inappro-
priate translocation of oncogenes from partner
chromosomes into the immunoglobulin heavy chain
switch region (IgH) locus on chromosome 14q32. In the
past several years, five recurring translocation partners
have been defined and mapped to the earliest stages of
the developing MM clone [2-4]. The translocations
involve partner oncogenes cyclin D1 (11q13), cyclin D3
(6p21), fibroblast growth factor receptor 3 (FGFR3,
4p16), c-maf (6q23) and mafB (20q11). These recurrent
translocations are identified with high frequency in pri-
mary patient samples and, between them, are found in
approximately 50% of MM [5,6]. The remaining 50% of
MM lack translocations and are characterized by chro-
mosomal duplication (hyperdiploidy) with associated up-
regulation of cyclins D1, D2 and D3 although the molecu-
lar pathogenesis is unclear [5]. An equally early event in
the genesis of MM appears to be loss of part of chromo-
some 13 at 13q14.3, although the specific tumor suppres-
sor gene(s) in this region have yet to be identified [7,8].
These events all occur early in disease onset and are often
present during an asymptomatic and stable form of the
disease called monoclonal gammopathy of unknown sig-
nificance or MGUS. Active disease must therefore
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require subsequent genetic events such as mutation/dele-
tion of p53 or Ras mutations [9].
We have evaluated the prognostic significance of recur-
rent genomic aberrations including del(13q), t(11:14)/
CyclinD1, t(4;14)/FGFR3, t(14;16)/c-Maf, del(17p)(p53),
1q21(CKS1B) amplification, 1p21/CDC14a deletion, and
PTEN deletions, as well as CD56 expression in large
cohorts of MM patients uniformly treated at our center
[10-26]. In addition we have evaluated the impact of
chromosomal aberrations on MM patients receiving
novel therapies such as the proteasome inhibitor, borte-
zomib or the immunomodulatory drug lenalidomide.
While high-risk genetic factors (t(4;14, del(17p)(p53)
deletion, or 13q deletion) did not affect the response or
survival of refractory/relapsed MM patients treated with
bortezomib [27], del(17p)(p53) deletion had a negative
influence on progression free and overall survival of MM
patients receiving lenalidomide and dexamethasone [28].
In addition to the cytogenetic studies which have given
us significant insight into MM diagnosis and prognosis,
gene-expression profiling of MM has also significantly
contributed to our understanding of this disease. Due to
the highly heterogeneous nature and complexity of MM,
gene expression profiling is well suited to study this can-
cer as it allows for the identification and differentiation of
hundreds of genes between various disease states. Several
groups have used gene expression arrays, for example, to
evaluate drug response in MM patients. Mulligan et al.
identified a pretreatment expression pattern and predic-
tive markers that could differentiate between bortezomib
and dexamethasone response [29]. Other groups have
used expression arrays to identify genes involved in doxo-
rubicin and dexamethasone resistance in MM [30,31].
Gene expression arrays have also been used to determine
the genetic differences between plasma cells and MGUS
and MM cells [32]. These studies have made significant
contributions to our understanding of the molecular
development as well as mechanisms of drug resistance of
MM.
A complementary approach to the study of gene
expression profiling is proteomic profiling. The advan-
tages of this approach, which has been increasing in pop-
ularity over the past several years, is the ability to
determine protein expression levels, post-translational
modifications and protein-protein interactions, all of
which may have a direct consequence to cell function;
such information cannot be obtained through gene
expression profiling. Furthermore, several studies found
that there is not a significant overlap between gene and
protein expression profiles [33-35]. Therefore direct
approaches to studying the protein profile of MM are
necessary.
Traditional methods to study proteins, such as western
blot analysis or immunohistochemistry, have their short-
comings as high throughput solutions for protein profil-
ing including the need for large amounts of tissue as well
as the availability of well-characterized antibodies. Mass
spectrometry techniques, on the other hand, offer a
robust, high throughput method that overcomes many of
these limitations [36]. Most important to cancer research,
mass spectrometry can be employed to identify known
and novel differentially expressed proteins between dif-
ferent tumor samples. This would allow for the identifica-
tion of biomarkers that can be used in diagnosis,
prognosis, and treatment assessment.
Mass Spectrometry
A mass spectrometer determines the mass of a molecule
by measuring its mass-to-charge ratio (m/z). Each mass
spectrometer consist of three components; i) the source,
w h i c h  g e n e r a t e s  i o n s  f r o m  a  s a m p l e  e i t h e r  b y  m a t r i x -
assisted laser desorption ionization (MALDI) or electro-
spray ionization (ESI), ii) a mass analyzer, which resolves
peptide ions according to their m/z ratio, and iii) a detec-
tor which determines ion abundance for each corre-
sponding ion resolved by the mass analyzer according to
their m/z value and generates a mass spectrum (Figure 1).
Depending on the type of mass spectrometer used, pep-
tide mass (MS) and/or peptide sequence (MS/MS) data
can be obtained from the mass spectrum. This informa-
tion is then used to search public databases for protein
identification such as those maintained by the National
Center for Biotechnology Information (NCBI) and the
European Bioinformatics Institute (EBI).
Mass Spectral Analysis
Biological samples including cell lines maintained in cul-
ture, biopsy specimens, and serum are very complex in
nature as they contain not only an abundance of proteins,
but also a large amount of lipids and nucleic acids [36].
Although the mass spectrometer is capable of resolving
complex mixtures, protein identification can be greatly
simplified if this complexity is reduced. Biological sam-
ples are typically lysed with detergents that solubilize
proteins, separating them from lipids and nucleic acids.
Subsequent procedures can then be employed to further
simplify the protein mixture. One dimensional gel elec-
trophoresis can be used to separate proteins according to
their molecular weight. Alternatively, two-dimensional
gel electrophoresis can be used to achieve greater protein
separation by resolving proteins according to their iso-
electric value (pI) and molecular weight. Following elec-
trophoresis proteins are stained with dyes such as
Coomassie blue, excised, digested "in-gel" into peptides
and then analyzed by the mass spectrometer. Although
gel electrophoresis is capable of reducing the complexity
of a mixture it has its limitations [37]. Most notably, gel
electrophoresis has a limited dynamic range of detectionMicallef et al. Journal of Hematology & Oncology 2010, 3:13
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as protein bands are excised only if they can be visualized
following staining. The level of detection by MS, however,
is below the level of detection of staining and hence many
relevant proteins may be missed. A further disadvantage
of 2D separation is that it is often difficult to reproduce
and some proteins cannot be resolved according to their
pI value [37].
An alternative method to reduce the complexity of a
protein mixture is the use of liquid chromatography (LC)
[36]. Typically, proteins are first digested into peptides
and then resolved by LC. The separation of peptides is
usually achieved according to charge and molecular
weight. Often, the peptides that are resolved by LC are
directly analyzed by the mass spectrometer. The main
a d v a n t a g e  o f  L C  i s  t h a t  t h i s  m e t h o d  a v o i d s  t h e  l o w
dynamic range limitation encountered by gel staining.
Quantitative Proteomics
In order to improve the diagnosis, prognosis and treat-
ment stratification of those afflicted by cancer the identi-
fication of biomarkers indicative of these parameters are
necessary. Quantitative protein analysis by mass spec-
trometry in which a tumor cell may be compared to a
normal cell or a drug resistant tumor cell is compared to a
drug sensitive tumor cell, provides an effective way to dis-
cover these biomarkers. There are two main methodolo-
gies to quantify proteins within a sample, stable isotope
Figure 1 The mass spectrometer. (A) Source. In ESI a liquid containing a protein/peptide mixture is passed through a high-voltage capillary tube 
resulting in charged peptides. In MALDI, a laser is used to excite a chemical matrix containing peptides leading to ejection of charged peptides into 
the gas phase. (B) Mass analyzers. The quadrupole uses both AC and DC current to affect the trajectory of incoming charged particles. The first qua-
drupole acts as a mass filter allowing only certain ions to pass into the second quadrupole, the collision cell, where they collide with a neutral gas, 
undergo fragmentation and enter into the third quadrupole that also acts as a mass filter. The ion-trap mass analyzer uses an AC voltage to "trap" ions. 
By increasing the AC amplitude, ions of increasing m/z ratio are ejected and measured by the detector. In Time of Flight (TOF), ions of different m/z 
values are injected into one end of the tube so that they each have approximately identical kinetic energy as they accelerate through the tube. Ions 
of less mass will reach the detector faster than those that are heavier. (C) Detector. As an ion strikes the surface of the electron multiplier detector, it 
causes the emission of electrons, which in turn results in the release of secondary electrons. This multiplication process results in the generation of 
100 million electrons per incident ion. The arrival of the electron pulse registers as a single ion count.
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labeling and label free methods. Both these techniques
have been widely used for biomarker discovery [38-45].
One of the most commonly used stable isotopes is the
isobaric tags for relative and absolute quantification
(iTRAQ). The iTRAQ method allows the simultaneous
comparison of up to 8 different samples. The iTRAQ
reagent labels the N-terminus of tryptic peptides as well
as the amino group side chain of lysine residues [36]. Pro-
teins from different samples are first digested to yield
peptides. Each peptide sample is then labeled with one of
the iTRAQ reagents. Each reagent consists of i) a reporter
group with a molecular weight of 113, 114, 115, 116, 117,
118, 119, or 121 Da; ii) a linker group that also varies in
molecular weight to 'balance' the difference of the
reporter group; and iii) a peptide reactive group that
reacts with the N-terminus of peptides and lysine side
chains. Labeled samples are then mixed together and
analyzed by the mass spectrometer. Collision induced
dissociation of iTRAQ-labeled peptides generates
sequence information as well as relative quantification
data between the samples.
Recent trends in discovery proteomics are now inclined
towards using label-free relative quantification based on
the linear relationship between sampling statistics
observed using LC-MS/MS and relative protein abun-
dance [46]. Sampling statistics evaluated as potential
measures of relative protein abundance include 1) the
mean peak area intensity of all peptides identified for an
individual protein in a complex sample [47]; 2) the pep-
tide count, or total number of peptides identified from a
given protein in a LC-MS/MS experiment [46,48]; and 3)
spectral counts, or the total number of tandem mass
spectra generated on a given peptide in an LC-MS/MS
experiment [47,49-52].
The use of label free techniques has several advantages
[53]. First it is more cost effective and less time consum-
ing compared to labeling methods since the labeling
reagents do not have to be purchased and experiments to
incorporate the stable isotopes into samples are bypassed.
Label free methods therefore require less sample modifi-
cation and avoid increasing sample complexity associated
with mixtures of tagged peptides. A second advantage of
label free methods is that theoretically there is no limit to
the number of samples that can be compared whereas
with isotope labeling such as iTRAQ a maximum of 8
samples can be compared at a time. Another advantage of
the label free method is that it may provide a higher
dynamic range in terms of quantification, although this
comes at the expense of unclear linearity and relatively
low accuracy [53]. Although there are several advantages
to label free methods, it is essential that these methods
are robust and reliable in order to control for any experi-
mental variables and that sample processing does affect
the outcome of analyses [54].
Mass Spectrometry to study Multiple Myeloma
Serum markers for MM diagnosis and prognosis
One of the greatest challenges we face in the clinical set-
ting is the development of tests that would allow for the
early detection of cancer. It is well accepted that the ear-
lier tumor cells are detected, the better the prognosis.
Certain cancers, including breast, colon and prostate can
be detected at an early stage through routine physical
exams. For example, screening for prostate specific anti-
gen (PSA) may be useful for the early detection of pros-
tate cancer. Unfortunately, there are no reliable
biomarkers that can be used for the early detection of
MM and patients are often diagnosed after presenting
with clinical manifestations.
A recent study has found that virtually all cases of MM
arise from MGUS [55]. On the other hand, the majority of
MGUS cases will not develop into MM. Although the sta-
tus of M-protein may offer insight into the development
of MM, it is not absolute, and thus there is a need to iden-
tify biomarkers that can predict progression to MM in
patients diagnosed with MGUS.
Several groups have been using mass spectrometry
based techniques in order to identify potential biomark-
ers that are early predictors of cancer development [56-
61]. Elucidation of these early biomarkers for various can-
cers, including MM, would be most easily identified from
plasma or serum. The advantage of screening blood is
that it is easily obtained and contains a large amount of
proteins which increase the likelihood of biomarker dis-
covery [62]. One strategy for the early detection of cancer
relies on the immune response, which is believed to make
auto-antibodies against cancer cells and because the
immune response involves an amplification process,
these antibodies may be present in sufficient quantities
for detection [63,64]. Regardless of the type of biomarker,
it will be essential that they are both tumor specific and
tissue specific so that the identification and location of
the tumor can be determined. Because an overlap most
likely exists in biomarker expression between different
tumor types, a panel of biomarkers would have to be
identified rather than relying on a single protein.
In addition to the identification of early biomarkers that
can predict MM, it is also clinically relevant to identify
markers that are used for the diagnosis and prognosis of
MM. Currently these include calcium, creatinine, hemo-
globin, albumin, beta2-microglobulin and monoclonal
antibodies. In addition, disease relapse can be monitored
by assessing the levels of monoclonal antibodies includ-
ing heavy chains as well as κ and λ light chains. Koomen's
group is currently developing mass spectral techniques
that will allow for the quantitative detection of immuno-
globulin associated peptides [65]. As MS analysis within
the clinical setting becomes more accepted and afford-
able, successful development of these tests could offerMicallef et al. Journal of Hematology & Oncology 2010, 3:13
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advantages over current clinical tests that are more quali-
tative in nature, slower, and of lower throughput [65].
Several groups are using mass spectrometry to identify
additional biomarkers that may allow for a more specific
and sensitive method to diagnose MM. Wang et al.
employed MALDI-TOF-MS and identified a panel of
three biomarkers that correctly identified 26 out of 30
(87%) MM patients and 34 out of 34 (100%) of all normal
donors [66]. However, these markers were unable to dif-
ferentiate between MM and other plasma cell dyscrasias
including MGUS, Waldenstrom's macroglobulinemia,
solitary plasmacytoma, as well as other tumors with
osseus metastasis. Therefore, as the authors mention, it
will be necessary to increase their samples size in order to
identify additional markers that may unequivocally iden-
tify MM patients. Nevertheless this work demonstrates
the usefulness of MALDI-TOF MS for the identification
of novel biomarkers.
Another group also used mass spectrometry to identify
serum biomarkers that might discriminate between
patients with skeletal involvement [67]. This group
screened serum samples from 48 patients either with evi-
dence of skeletal involvement (24 patients) or without
evidence of skeletal involvement (24 patients). Using a
partial least squares discriminant analysis (PLS-DA), and
a non-linear, random forest (RF) classification algorithm,
they were able to predict skeletal involvement with an
accuracy between 96-100% using the PLS-DA model and
obtained a specificity and sensitivity of 87.5% each with
the RF model based on four peaks. Although this study
demonstrates the usefulness of proteomic profiling in the
diagnosis and treatment of MM progression, further vali-
dation studies in additional patient samples are needed.
Proteins that confer drug resistance in Multiple Myeloma
As mentioned earlier, MM remains a largely incurable
disease despite a plethora of chemotherapeutic drugs.
This is mainly due to the acquisition of drug resistance by
tumor cells. The molecular mechanisms responsible for
drug resistance are not well understood. Moreover, it is
likely these resistance pathways are unique for each drug.
Two scenarios can be envisioned in the acquisition of
drug resistance. First, tumor cells may express proteins
prior to drug treatment that will render them resistant,
and second, tumor cells may acquire resistance following
drug administration. An understanding of the molecular
signatures that confer drug resistance will be of signifi-
cant benefit in treatment stratification and will enable the
design of novel therapeutic strategies.
Bortezomib
Bortezomib, a proteasome inhibitor, has been approved
for the treatment of MM patients who have received at
least two prior therapies and progressed during the last
treatment [68-70]. This drug has been shown to induce
apoptosis in various cancer cells, including MM and
other lymphomas. It also affects nuclear factor-kB (NF-
kB), the bone marrow microenvironment and various
cytokine interactions, including, IL-6 [68-70]. Despite
significant benefits with regards to time to progression,
overall survival and a trend to a lower incidence of infec-
tions >grade 3, bortezomib induced an overall response
rate of only 35% in refractory and relapsed MM patients
(pivotal phase-II (SUMMIT) trial) [68]. In order to deter-
mine if recurrent molecular cytogenetic changes identi-
fied in MM contribute to the response of bortezomib
therapy, we used fluorescence in situ hybridization com-
bined with cytoplasmic immunoglobulin light chain
stainings (cIg-FISH) and found that the response to bort-
ezomib was independent of recurrent genomic aberra-
tions in MM patients [27]. These observations were
confirmed by two independent research groups [71,72].
In light of the above observations, our group is taking a
proteomic based approach in order to identify biomark-
ers that may predict and contribute to bortezomib resis-
tance. To undertake this study we have used iTRAQ
analysis to identify differentially expressed proteins
between the 8226/R5 bortezomib resistant multiple
myeloma cell line and the 8226/S bortezomib sensitive
multiple myeloma cell line. Using this approach we iden-
tified 30 proteins that were either significantly up or
down regulated in the 8226/R5 cell line compared to the
8226/S cell line [73]. Biological systems analysis of these
putative markers using Ingenuity Pathway Analysis soft-
ware revealed that they were associated with cancer-rele-
vant networks (Figure 2). Of particular interest is the
MARCKS protein which we found to be over-expressed
in the 8226/R5 cell line. MARCKS is a PKC substrate pro-
tein that has been found to be over-expressed in several
cancers, including glioblastoma multiforme where it was
shown to play a role in glioma cell invasion [74]. We have
shown that MARCKS is over-expressed in 9 (50%) of 18
multiple myeloma cell lines. In addition, a preliminary
screen of pre-bortezomib treatment MM patient samples
by immunohistochemistry showed over-expression of
MARCKS is associated with bortezomib resistance. W e
are currently evaluating whether MARCKS plays a role in
drug resistance and/or contributes to other tumorgenic
properties of MM.
Protein expression data obtained from our iTRAQ
analysis comparing 8226/R5 versus 8226/S cell lines was
also compared with gene expression array data from the
literature that contrasted MM bortezomib resistant to
bortezomib sensitive cells. As expected, there was mini-
mal overlap between these datasets. However these lists
of genes and proteins showed strong complementarity in
terms of the functional and biological systems with which
they are associated, suggesting the systems affected by
them or those which they affect may be closely inter-Micallef et al. Journal of Hematology & Oncology 2010, 3:13
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related (as illustrated by the network diagram in Figure
3). These data demonstrate the usefulness of proteomic
profiling over conventional gene array approaches.
Recently, Hsieh et al. used mass spectrometry to iden-
tify early biomarkers of bortezomib resistance from the
serum of MM patients [75]. They found both apolipopro-
tein C-I and apolipoprotein C-I' to be significantly more
abundant in the non-responsive patients compared to the
responsive patients 24-hours post drug administration.
The results suggest that apolipoprotein C-I and apolipo-
protein C-I' may be used as early biomarkers for borte-
zomib drug resistance. However, it will be necessary to
carry out a time course experiment in a larger sample size
in order to validate these findings. Additional experi-
ments are required to determine the functional relation-
ship between these proteins and bortezomib response.
Dexamethasone
Dexamethasone (dex) is a synthetic steroid hormone that
is also used in the treatment of MM. Clinical trials have
shown response rates of up to 70% in MM patients [76].
Additional clinical trials observed a synergistic response
when dex was used in combination with other drugs such
as bortezomib and thalidomide [68,77]. The mechanisms
of action of these drugs, however, are not well under-
stood. In an attempt to improve clinical response Ress-
Unwin et al. used mass spectrometry to identify proteins
that may play a role in dex induced apoptosis [76]. They
found a panel of proteins that were differentially
Figure 2 Highest scoring molecular interaction network generated from Ingenuity Pathways Analysis (IPA) software. Top functional anno-
tations associated with this network were "Cancer", "Cellular Assembly and Organization", and "Cellular Function and Maintenance". Up-regulated 
(red) and down-regulated (green) proteins in the 8226/R5 cell line detected in the iTRAQ-MS study are connected by additional protein interactors 
(white). Both direct and indirect interactions are shown (solid and dashed lines, respectively) with arrows indicating the direction of the underlying 
relationship, where applicable; types of interactions include activation (A), expression (E), localization (L), membership (MB), phosphorylation (P), pro-
tein-DNA (PD), protein-protein (PP), regulation of binding (RB), and translocation (TR). Network analysis was performed on differentially expressed pro-
teins using the Core Analysis feature in IPA version 6.2, and the following analysis settings: data source: Ingenuity Expert Findings; species: human, 
mouse, rat, uncategorized; tissues and cell lines: all selected.Micallef et al. Journal of Hematology & Oncology 2010, 3:13
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expressed following dex treatment in the sensitive MM1S
multiple myeloma cell line compared to the resistant
MM1R cell line. Most notably, they identified FK binding
protein 5 (FKBP5), which is involved in protein folding
and trafficking to be over-expressed in the MM1S but not
the MM1R cell line following dex treatment. These data
are important as they shed light onto the signaling path-
ways that may induce dex-mediated apoptosis and thus
may help direct rational drug design. However, before
this is realized it will be necessary to gain further insight
into the signaling pathways in which these proteins are
acting.
Arsenic trioxide
Arsenic trioxide (ATO) has been shown to induce growth
inhibition and apoptosis in MM cells and has shown clin-
ical activity in both Phase I and II clinical trials in patients
with relapsed or refractory MM [78]. In order to deter-
mine the mechanisms of ATO activity, Ge et al. used 2D
gel electrophoresis coupled with MALDI TOF/TOF anal-
ysis to evaluate proteins altered following ATO activity in
Figure 3 Comparison of protein and gene expression studies. Interaction network diagram combining a subset of differentially expressed pro-
teins detected in iTRAQ-MS pilot study, and gene products from two microarray-based gene expression studies investigating bortezomib resistance 
[29,89]. Up-regulated (red) and down-regulated (green) proteins in the 8226/R5 cell line from each of the three studies are connected by intermediate 
interactors (white). Expression of DEK oncogene was observed in both iTRAQ-MS and Mulligan [29] studies; proteasome (prosome, macropain) 26S 
subunit non-ATPase 1 (PSMD1) was expressed in both iTRAQ-MS and Buzzeo [89] studies. Integration of the pilot proteomics data with gene expres-
sion datasets indicates complimentarity at the protein interaction and pathway level. Differentially expressed proteins (fold-change = 1.5) measured 
by iTRAQ-MS are shown to interact directly with a number of oncogenic signaling molecules including TP53, c-Myc, NF-kB, STAT, and PI3K, suggesting 
possible roles as upstream effectors or indicators of anti-apoptotic and/or tumorgenic processes. Other direct interactors of measured proteins in-
clude therapeutic targets in multiple myeloma, including PSMB5 (bortezomib), CDK2 (flavopiridol), and RRM2 (fludarabine phosphate). Protein inter-
actions and illustration were generated with Ingenuity Pathways Analysis version 8.0-2602. Protein interactions were restricted to direct types (default 
selections) with the term "cancer" as a disease annotation in human/mouse/rat and in uncategorized species.Micallef et al. Journal of Hematology & Oncology 2010, 3:13
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the U266 multiple myeloma cell line [78]. The most sig-
nificant changes were observed in the up-regulation of
HSP proteins and down regulation of 14-3-3ζ protein and
the members of the ubiquitin-proteasome system follow-
ing ATO treatment. This group further demonstrated
that the use of 14-3-3ζ siRNA potentiated the effects of
ATO induced apoptosis whereas over-expression 14-3-3ζ
reduced ATO-sensitivity in U266 cells. Furthermore, they
showed that inhibition of HSP90, which is over-expressed
following ATO treatment, sensitized cells to ATO treat-
ment as well as potentiated the effect of 14-3-3ζ knock-
down. These results demonstrate the usefulness of
identifying additional therapeutic targets that may be
exploited to over-come drug resistance.
Post translation modifications of the MM proteome
Post-translation modifications (PTMs) play an important
role in the maturation and regulation of proteins. One of
the most common PTMs is phosphorylation. Phosphory-
lation of proteins is carried out by specific protein kinases
and occurs at three specific residues: serine, threonine,
and tyrosine. Protein dephosphorylation, on the other
hand is carried out by phosphatases. Protein activity is
controlled by cycles of phosphorylation and dephospho-
rylation. Because protein phosphorylation is crucial to
protein activity and thus regulation of cellular behavior,
knowledge of protein phosphorylation status within the
cell would give significant insight into signaling mecha-
nisms. Furthermore, this may help in the design of kinase
or phosphatase inhibitors in an attempt to control cellular
events.
In MM, several proteins are regulated through phos-
phorylation events, including fibroblast growth factor
receptor-3 (FGFR3). Activation of FGFR3, through
tyrosine phosphorylation, induces cell growth, survival
and migration through activation of various signaling
pathways including MAPK and PI3K [79,80]. Aberrant
activation of FGFR3 has been observed in 15-20% of MM
due to a t(4;14)(p16.3;q32) translocation and has been
shown to contribute to the tumorgenesis of MM, includ-
ing chemoresistance [81-83]. For these reasons several
drugs have been designed to target this receptor [84].
The signaling networks activated downstream of
FGFR3 are not fully known. Recently, St-Germain et al.
studied the phosphotyrosine proteomic profile associated
with FGFR3 expression, ligand activation, and drug inhi-
bition in the KMS11 MM cell line by mass spectrometry
[85]. They identified and quantified several phosphoty-
rosine sites as a result of FGFR3 activation and drug inhi-
bition. Their results have substantially increased our
understanding of FGFR3 function and provided a frame-
work for studying appropriate signaling networks acti-
vated by this receptor in MM. Importantly their mass
spectrometry approach demonstrated the potential for
pharmacodynamic monitoring.
The future of mass spectrometry in biomarker 
discovery
The use of mass spectrometry for biomarker discovery
holds great promise. In order for this to be fully realized
in the clinical setting however, various limitations must
be addressed [62]. First, there exists a limited dynamic
range for even the most sensitive mass spectrometers.
Highly abundant proteins, such as albumin can mask less
abundant proteins which may be important biomarkers.
This is especially true during the early stages of tumor
development when tumor biomarkers may be low and so
care must be taken to simplify samples. Through sample
purification, however, low-abundant proteins maybe lost
through interactions with high abundant proteins such as
albumin. Thus, all purifications steps should be analyzed.
It will also be important that biomarkers are validated
in large, independent studies before entering the clinic.
T o  t h i s  e n d ,  i t  w i l l  b e  n e c e s s a r y  t o  s t a n d a r d i z e  t h e s e
experiments in terms of sample collection, storage and
processing as well as bio-informatics and statistical analy-
sis between various centers. Furthermore, careful consid-
eration will need to be given to the normal group to
which the cancer group is compared. Differences in age,
sex, and ethnicity, as well as menopausal and nutritional
status may all be confounding variables in biomarker dis-
covery [86,87].
Although both cell lines and clinical specimens are
valuable samples for biomarker discovery, they each have
their limitations. Most notably, cell lines do not represent
an in vivo model. Therefore, the influence of the
microenvironment on the tumor biomarker signature
cannot be evaluated resulting in potential misrepresenta-
tion of the true biomarkers. In terms of clinical speci-
mens, as discussed above, the many confounding variable
associated when comparing tumor to normal tissue also
represents a hurdle impeding biomarker discovery. An
alternative to these approaches is the use of genetically
engineered mouse models. These mouse models offer the
opportunity to standardize experiments through homog-
enized breeding and environmental control and by defin-
ing stages of tumor development [64]. Importantly it has
been observed that the tumor antigen repertoire of
tumor-bearing transgenic mice can predict human tumor
antigens [88].
Conclusion
The use of mass spectral analysis will prove to be a valu-
able tool for the diagnosis, prognosis and response to
drug treatment in cancer. Studies that have been carried
out in MM have increased our understanding of this can-Micallef et al. Journal of Hematology & Oncology 2010, 3:13
http://www.jhoonline.org/content/3/1/13
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cer; they have identified new serum biomarkers that may
distinguish between MM and normal patients as well as
serum markers that may identify patients with skeletal
involvement. In addition, mass spectrometry has been
used to identify biomarkers that indicate resistance to
several chemotherapeutic drugs used to treat MM.
Equally important mass spectrometry was used to inves-
tigate the phosphotyrosine signaling pathways down-
stream of FGFR3. These types of studies, that investigate
signaling networks, are essential as they will help guide
future investigations into the pathogenesis of MM.
Perhaps one of the greatest promises of mass spectrom-
etry will be its use in helping direct therapy. Since current
"one size fits all" therapy is complicated by serious toxici-
ties and may be unnecessary in some good prognosis
patients, it is critical to introduce risk-adapted therapy.
The development of risk-adapted therapy requires better
prognostic markers as the current prognostic models
remain inadequate to predict disease outcome for indi-
vidual patients. Through protein expression profiling by
mass spectrometry we will be able to identify biomarkers
that can be used to improve the diagnosis and prognosis
o f  M M  a s  w e l l  a s  i n c r e a s e  o u r  u n d e r s t a n d i n g  o f  t h e
mechanisms of drug resistance, which will help direct
therapeutic strategies.
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